Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoption
PLOS Medicine · 2026
DOI: 10.1371/journal.pmed.1004900 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Medicine, 2026. Verfasst von Luke J Laffin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, United Stat…. Hauptthemen laut MEDLINE: Hypertension, Cytochrome P-450 CYP11B2, Antihypertensive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite many antihypertensive options, uncontrolled hypertension remains pervasive. Aldosterone synthase inhibitors show robust blood pressure reductions and have the potential to reshape hypertension treatment, though cost and access may impact broad adoption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America.
- Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America.
ORCID-Profile: Luke J Laffin
Zitieren
APA
Laffin, L. J., & Nissen, S. E. (2026). Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoption. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004900
Vancouver
Laffin LJ, Nissen SE. Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoption. PLOS Medicine. 2026. doi:10.1371/journal.pmed.1004900
BibTeX
@article{Laffin2026,
author = {Laffin, Luke J and Nissen, Steven E},
title = {Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoption},
journal = {PLOS Medicine},
year = {2026},
doi = {10.1371/journal.pmed.1004900}
}
EUVIMED